NeoImmuneTech

Industry · 6 registered clinical trials.

Status	Trial	Phase	Started
Active Not Recruiting	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastat Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma	Phase 2	2021-11-03
Completed	Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma	Phase 1	2021-08-06
Terminated	NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcino Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)	Phase 1	2021-01-21
Terminated	A Trial of NT-I7 in COVID-19 (SPESELPIS) COVID-19	Phase 1	2020-11-27
Completed	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer	Phase 1 / Phase 2	2020-06-10
Terminated	High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma	Phase 1 / Phase 2	2019-12-26